Which regimen aligns with moderate persistent asthma management as described in the material?

Which regimen aligns with moderate persistent asthma management as described in the material?

• A. Albuterol as needed plus low-dose ICS plus LABA
• B. Albuterol as needed only
• C. High-dose ICS alone
• D. Montelukast monotherapy

Answer: (A)

Managing moderate persistent asthma relies on daily controller therapy to suppress airway inflammation, typically with an inhaled corticosteroid, and added bronchodilation from a long-acting beta-agonist to improve symptom control and reduce exacerbations. A rescue inhaler is kept on hand for immediate relief of acute symptoms. The regimen that includes albuterol as needed for quick relief, plus a low-dose inhaled corticosteroid combined with a long-acting beta-agonist as ongoing controller therapy, aligns with this approach. The ICS provides the anti-inflammatory effect essential for moderate persistent asthma, and the LABA enhances bronchodilation and control when daily symptoms are present. This combination addresses both the inflammatory and bronchoconstrictive aspects of the condition. Using albuterol alone offers only temporary relief without addressing inflammation, so it doesn’t meet the needs of moderate persistent asthma. A high-dose ICS without a LABA may provide stronger anti-inflammatory effects but lacks the additional bronchodilation that improves control in many patients. Montelukast monotherapy lacks the robust anti-inflammatory and bronchodilating impact needed for moderate persistent asthma and is not the preferred first-line regimen for this level of control.

Managing moderate persistent asthma relies on daily controller therapy to suppress airway inflammation, typically with an inhaled corticosteroid, and added bronchodilation from a long-acting beta-agonist to improve symptom control and reduce exacerbations. A rescue inhaler is kept on hand for immediate relief of acute symptoms.

The regimen that includes albuterol as needed for quick relief, plus a low-dose inhaled corticosteroid combined with a long-acting beta-agonist as ongoing controller therapy, aligns with this approach. The ICS provides the anti-inflammatory effect essential for moderate persistent asthma, and the LABA enhances bronchodilation and control when daily symptoms are present. This combination addresses both the inflammatory and bronchoconstrictive aspects of the condition.

Using albuterol alone offers only temporary relief without addressing inflammation, so it doesn’t meet the needs of moderate persistent asthma. A high-dose ICS without a LABA may provide stronger anti-inflammatory effects but lacks the additional bronchodilation that improves control in many patients. Montelukast monotherapy lacks the robust anti-inflammatory and bronchodilating impact needed for moderate persistent asthma and is not the preferred first-line regimen for this level of control.